BACKGROUND AND OBJECTIVES: In the albumin-to-creatinine ratio (spot-ACR), urine creatinine corrects for tonicity but also reflects muscle mass. Low muscle mass is associated with cardiovascular disease (CVD). We hypothesized that the spot-ACR would be higher in women, lower-weight persons, and older individuals, independent of timed urine albumin excretion (24hr-UAE), and accordingly, that spot-ACR would be more strongly associated with CVD events than 24hr-UAE in these subgroups. DESIGN, SETTING, PARTICIPANTS, & METHODS: 2627 PREVEND (Prevention of Renal and Vascular End-stage Disease) participants with 24hr-UAE <30 mg/d were followed for CVD events for 11 years. Cox regression evaluated associations of spot-ACR and 24hr-UAE with CVD events by sex, weight, and age. RESULTS: Female sex (26%), lower weight (2% per 5 kg), and older age (4% per 5 years) were associated with higher spot-ACR independent of 24hr-UAE (P<0.001). Spot urine albumin concentration (hazard ratio [HR], 1.26 per ln-SD higher) and 1/spot urine creatinine concentration (HR, 1.16 per ln-SD higher) were associated with CVD events. Spot-ACR was more strongly associated with CVD events than either component of the ratio (HR, 1.41 per ln-SD higher). Associations of spot-ACR ≥10 mg/g versus less (HR, 2.33) and 24hr-UAE ≥10 mg/d versus less (HR, 2.09) with CVD events were similar, and there were no significant differences across subgroups (P for interactions >0.06). CONCLUSIONS: In community-living individuals with 24hr-UAE <30 mg/d, spot-ACR is higher in women, older persons, and lower-weight persons, independent of 24hr-UAE. Low spot urine creatinine is associated with CVD risk, but high urine albumin is a stronger determinant of the association of spot-ACR with CVD than is low urine creatinine.
BACKGROUND AND OBJECTIVES: In the albumin-to-creatinine ratio (spot-ACR), urine creatinine corrects for tonicity but also reflects muscle mass. Low muscle mass is associated with cardiovascular disease (CVD). We hypothesized that the spot-ACR would be higher in women, lower-weight persons, and older individuals, independent of timed urine albumin excretion (24hr-UAE), and accordingly, that spot-ACR would be more strongly associated with CVD events than 24hr-UAE in these subgroups. DESIGN, SETTING, PARTICIPANTS, & METHODS: 2627 PREVEND (Prevention of Renal and Vascular End-stage Disease) participants with 24hr-UAE <30 mg/d were followed for CVD events for 11 years. Cox regression evaluated associations of spot-ACR and 24hr-UAE with CVD events by sex, weight, and age. RESULTS: Female sex (26%), lower weight (2% per 5 kg), and older age (4% per 5 years) were associated with higher spot-ACR independent of 24hr-UAE (P<0.001). Spot urine albumin concentration (hazard ratio [HR], 1.26 per ln-SD higher) and 1/spot urine creatinine concentration (HR, 1.16 per ln-SD higher) were associated with CVD events. Spot-ACR was more strongly associated with CVD events than either component of the ratio (HR, 1.41 per ln-SD higher). Associations of spot-ACR ≥10 mg/g versus less (HR, 2.33) and 24hr-UAE ≥10 mg/d versus less (HR, 2.09) with CVD events were similar, and there were no significant differences across subgroups (P for interactions >0.06). CONCLUSIONS: In community-living individuals with 24hr-UAE <30 mg/d, spot-ACR is higher in women, older persons, and lower-weight persons, independent of 24hr-UAE. Low spot urine creatinine is associated with CVD risk, but high urine albumin is a stronger determinant of the association of spot-ACR with CVD than is low urine creatinine.
Authors: M Roest; J D Banga; W M Janssen; D E Grobbee; J J Sixma; P E de Jong; D de Zeeuw; Y T van Der Schouw Journal: Circulation Date: 2001-06-26 Impact factor: 29.690
Authors: Andrew S Levey; Paul E de Jong; Josef Coresh; Meguid El Nahas; Brad C Astor; Kunihiro Matsushita; Ron T Gansevoort; Bertram L Kasiske; Kai-Uwe Eckardt Journal: Kidney Int Date: 2010-12-08 Impact factor: 10.612
Authors: Qing He; Moonseong Heo; Stanley Heshka; Jack Wang; Richard N Pierson; Jeanine Albu; Zimian Wang; Steven B Heymsfield; Dympna Gallagher Journal: Am J Clin Nutr Date: 2003-07 Impact factor: 7.045
Authors: Caitlin E Carter; Ronit Katz; Holly Kramer; Ian H de Boer; Bryan R Kestenbaum; Carmen A Peralta; David Siscovick; Mark J Sarnak; Andrew S Levey; Lesley A S Inker; Matthew A Allison; Michael H Criqui; Michael G Shlipak; Joachim H Ix Journal: Am J Kidney Dis Date: 2013-07-02 Impact factor: 8.860
Authors: Joseph A Abdelmalek; Ron T Gansevoort; Hiddo J Lambers Heerspink; Joachim H Ix; Dena E Rifkin Journal: Am J Kidney Dis Date: 2013-12-21 Impact factor: 8.860
Authors: Jacob J E Koopman; Rebecca Scherzer; Joachim H Ix; Michael G Shlipak; Sushrut S Waikar Journal: Clin J Am Soc Nephrol Date: 2020-09-14 Impact factor: 8.237
Authors: Joshua I Barzilay; Petra Buzkova; Michael G Shlipak; Mary F Lyles; Nisha Bansal; Pranav S Garimella; Joachim H Ix; Jorge R Kizer; Elsa S Strotmeyer; Luc Djousse; Mary L Biggs; David Siscovick; Kenneth J Mukamal Journal: J Am Geriatr Soc Date: 2021-08-07 Impact factor: 5.562